Drugs / luminespib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01854034 | Jul 2013 → Mar 2017 | non-small cell lung carcinoma | Massachusetts General Hospital | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | luminespib | “We report the final results of a phase II trial evaluating the activity of the Hsp90 inhibitor luminespib (AUY922) in NSCLC patients with EGFR ins20.” PMID 30351341 ↗ Oct 2018 |
| Known as | AUY922 | “We report the final results of a phase II trial evaluating the activity of the Hsp90 inhibitor luminespib (AUY922) in NSCLC patients with EGFR ins20.” PMID 30351341 ↗ Oct 2018 |
| Action | Inhibit | “Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers” PMID 30351341 ↗ Oct 2018 |